Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-04-25 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1915075

Yael Cohen-Sharir, Uri Ben-David

引用次数: 2

Abstract

Aneuploidy, a common feature of cancer cells, results in increased sensitivity to the inhibition of the spindle assembly checkpoint (SAC) and the mitotic motor protein Kinesin Family Member 18A (KIF18A). We discuss the importance of drugs targeting SAC core members and KIF18A. We stress the need to assess the sensitivity to this class of drugs at appropriate time points, and propose that aneuploidy could serve as a biomarker to stratify patients for SAC-targeting treatments.

查看原文本刊更多论文

非整倍性与针对纺锤体组装检查点和KIF18A的癌症治疗的相关性。

非整倍性是癌细胞的一个共同特征，导致对纺锤体组装检查点(SAC)和有丝分裂运动蛋白激酶家族成员18A (KIF18A)抑制的敏感性增加。我们讨论了针对SAC核心成员和KIF18A的药物的重要性。我们强调有必要在适当的时间点评估对这类药物的敏感性，并提出非整倍体可以作为一种生物标志物，用于对sac靶向治疗的患者进行分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.